TY - JOUR
T1 - Development of a full-length human protein production pipeline
AU - Saul, Justin
AU - Petritis, Brianne
AU - Sau, Sujay
AU - Rauf, Femina
AU - Gaskin, Michael
AU - Ober-Reynolds, Benjamin
AU - Mineyev, Irina
AU - Magee, Dewey
AU - Chaput, John
AU - Qiu, Ji
AU - LaBaer, Joshua
PY - 2014/8
Y1 - 2014/8
N2 - There are many proteomic applications that require large collections of purified protein, but parallel production of large numbers of different proteins remains a very challenging task. To help meet the needs of the scientific community, we have developed a human protein production pipeline. Using high-throughput (HT) methods, we transferred the genes of 31 full-length proteins into three expression vectors, and expressed the collection as N-terminal HaloTag fusion proteins in Escherichia coli and two commercial cell-free (CF) systems, wheat germ extract (WGE) and HeLa cell extract (HCE). Expression was assessed by labeling the fusion proteins specifically and covalently with a fluorescent HaloTag ligand and detecting its fluorescence on a LabChipVR GX microfluidic capillary gel electrophoresis instrument. This automated, HT assay provided both qualitative and quantitative assessment of recombinant protein. E. coli was only capable of expressing 20% of the test collection in the supernatant fraction with ≥20 μg yields, whereas CF systems had ≥83% success rates. We purified expressed proteins using an automated HaloTag purification method. We purified 20, 33, and 42% of the test collection from E. coli, WGE, and HCE, respectively, with yields ≥1 μg and ≥90% purity. Based on these observations, we have developed a triage strategy for producing full-length human proteins in these three expression systems.
AB - There are many proteomic applications that require large collections of purified protein, but parallel production of large numbers of different proteins remains a very challenging task. To help meet the needs of the scientific community, we have developed a human protein production pipeline. Using high-throughput (HT) methods, we transferred the genes of 31 full-length proteins into three expression vectors, and expressed the collection as N-terminal HaloTag fusion proteins in Escherichia coli and two commercial cell-free (CF) systems, wheat germ extract (WGE) and HeLa cell extract (HCE). Expression was assessed by labeling the fusion proteins specifically and covalently with a fluorescent HaloTag ligand and detecting its fluorescence on a LabChipVR GX microfluidic capillary gel electrophoresis instrument. This automated, HT assay provided both qualitative and quantitative assessment of recombinant protein. E. coli was only capable of expressing 20% of the test collection in the supernatant fraction with ≥20 μg yields, whereas CF systems had ≥83% success rates. We purified expressed proteins using an automated HaloTag purification method. We purified 20, 33, and 42% of the test collection from E. coli, WGE, and HCE, respectively, with yields ≥1 μg and ≥90% purity. Based on these observations, we have developed a triage strategy for producing full-length human proteins in these three expression systems.
UR - http://www.scopus.com/inward/record.url?scp=84906853591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906853591&partnerID=8YFLogxK
U2 - 10.1002/pro.2484
DO - 10.1002/pro.2484
M3 - Article
C2 - 24806540
AN - SCOPUS:84906853591
SN - 0961-8368
VL - 23
SP - 1123
EP - 1135
JO - Protein Science
JF - Protein Science
IS - 8
ER -